Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Handrean Soran, Central Manchester University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01054508
First received: January 21, 2010
Last updated: October 10, 2012
Last verified: January 2011

January 21, 2010
October 10, 2012
June 2010
January 2012   (final data collection date for primary outcome measure)
The investigators expect the majority (90% or more) of patients to achieve a 15% increase in HDL level. [ Time Frame: 14 months ] [ Designated as safety issue: No ]
We expect the majority (90% or more) of patients to achieve a 15% increase in HDL level. [ Time Frame: 14 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01054508 on ClinicalTrials.gov Archive Site
Changes in paraoxonase activity, changes in oxidised LDL, changes in glycated LDL, changes in HDL inflammatory index. [ Time Frame: 14 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers
Effect of Tredaptive on Serum Lipoproteins, Lipoproteins Metabolism, Oxidative Stress and HDL Antioxidant Function

Cardiovascular disease (CVD) is associated with high levels of low-density lipoprotein (LDL) cholesterol and low levels of high-density lipoprotein (HDL) cholesterol.

CVD results from 'hardening of the arteries' when there is a build-up of cholesterol in the walls of blood vessels. LDL is the main carrier of cholesterol in the body. LDL particles are responsible for transporting cholesterol that is deposited in vessel walls. LDL particles can also be altered in structure and turn into an irritant to the vessel walls. The body responds to the irritating effect of LDL by producing substances that result in inflammation. This sequence of events eventually leads to the vessels becoming permanently damaged. HDL has a protective role in CVD. It is associated with the enzyme paraoxonase which protects the body from the damaging effects of altered LDL particles.

Nicotinic acid (niacin) has the ability to lower LDL levels and raise HDL levels thus reducing the incidence of CVD. Our study aims to show that niacin not only has good effects on cholesterol levels but is also able to reduce inflammation. Niacin is often poorly tolerated due to flushing side effect. Tredaptive is a formulation that combines niacin with laropiprant, an agent that reduces flushing hence improving tolerability and compliance.

Patients who are receiving cholesterol-lowering medication and whose LDL levels have not reached the recommended target are recruited to the study. The study will be conducted at the Manchester Royal Infirmary. The study has two consecutive 16 week periods. In each period patients will be randomised to either tredaptive or placebo. They will attend for 5 monitoring visits. Apart from the first visit, fasting blood samples will be taken from them during all subsequent visits.

The design is a placebo-controlled cross-over study. The study has 2 consecutive 16 week periods. If a patient satisfies the inclusion/exclusion criteria and consents to participate in the study, he/she will enter a 4-week placebo run-in period. This is followed by a 12-week treatment period where the patient will be assigned tredaptive or placebo randomly. At the end of the treatment period the patient will enter a second 4-week placebo period before going onto the second 12-week treatment period. Patients who are randomised to placebo in the first treatment period will receive tredaptive in the second treatment period and vice versa. Thus all participating patients will receive active medication for one treatment period in the study.

Patients will continue taking statins for the duration of the study, ensuring the cholesterol-lowering benefits they have from their usual medication are not compromised.

Patients will be recruited from the Lipid Clinic at the Manchester Royal Infirmary. The study will be explained fully to the patients who will have time to ask questions. Information leaflets will be given to patients who will be encouraged to take at least 1 day to discuss the study with their families, friends and general practitioners before consenting.

The study comprises 5 visits. At the first visit, informed consent will be taken from the patients. The visit also includes history taking and physical examination. Subsequent visits take place at the end of 4th and 16th weeks. This is repeated for the second 16 week period. Apart from the first visit, patients will be required to give a blood sample of 50 ml at each of the visits. They will be asked to fast overnight (from 22.00 hours) the day before the visit and blood sampling will be done before midday the following day. Blood will be taken by an experienced doctor or nurse and the only risks involved may be bruising at the puncture site.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Hypercholesterolemia
Drug: nicotinic acid/laropiprant
Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
Other Name: Tredaptive
Tredaptive
Patients on Tredaptive are expected to have 15% increase in HDL cholesterol.
Intervention: Drug: nicotinic acid/laropiprant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
38
January 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women who are taking cholesterol-lowering medication (maximum tolerated statins and/or ezetimibe) and who have not reached the recommended LDL target of less than 1.8 mmol/l (70 mg/l). Ezetimibe will be stopped 4 weeks before entering the study.

Exclusion Criteria:

  • Pregnant and/or breast-feeding women. Significant renal impairment (eGFR < 59ml/min). Active liver disease and transaminases > 3 times upper limit of normal range. Patients on fibrates. Patients on Omacor. Patients who are allergic to nicotinic acid.
Both
20 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01054508
TRED012010
No
Handrean Soran, Central Manchester University Hospitals NHS Foundation Trust
Central Manchester University Hospitals NHS Foundation Trust
Not Provided
Principal Investigator: Handrean Soran, MRCP Central Manchester University Hospitals NHS Foundation Trust
Central Manchester University Hospitals NHS Foundation Trust
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP